Siga Technologies – SIGA Announces start if TPOXX® Post-Exposure Prophylactic (“PEP”) Clinical Trials


SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has initiated the clinical program to support a U.S. Food and Drug Administration (FDA) label expansion for Post-Exposure Prophylaxis (“PEP”) for oral TPOXX®, approved in July 2018 for the treatment of smallpox. The first study is a comparison of the enrolled participants’ immune response with the Jynneos smallpox vaccines compared with the immune response with Jynneos while on TPOXX treatment. The study is designed to determine if TPOXX interferes with the development of an effective immune response to the vaccine.

Read more about this news here.

Related articles

Recent articles